Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Chinese Medical JournalOpen Access

Comparable survival outcomes for secondary and de novo acute myeloid leukemia after haploidentical hematopoietic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

KZKehan ZhangPeking UniversityYCYingjun ChangChinese Academy of Medical Sciences & Peking Union Medical CollegeYSYuqian SunPeking University

Discussion

Loading...

Member takes

Implication

Retrospective study compares survival outcomes in secondary and de novo acute myeloid leukemia after haplo-HSCT, suggesting comparable prognoses.

Key Points

  • The study aims to compare clinical outcomes after haplo-HSCT between patients with de novo AML and sAML.
  • Retrospective analysis of 248 de novo AML and 47 sAML patients undergoing haplo-HSCT from 2019 to 2022.
  • Utilized propensity score matching to balance confounding factors between the patient groups.
  • Analyzed outcomes like graft-versus-host disease, recovery rates, and survival metrics.
  • 2-year overall survival rates were 90.7% for de novo AML and 88.9% for sAML (P = 0.769).
  • No significant differences in cumulative incidence of relapse (23.7% de novo vs. 10.9% sAML, P = 0.116) or non-relapse mortality.
  • Pretransplant measurable residual disease was identified as an adverse factor for relapse and survival outcomes.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a192eb9fab5b468c4417ff9https://doi.org/10.1097/cm9.0000000000004124
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China2024 · 13 citations
  2. 2Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial2024 · 14 citations
  3. 3Patients with secondary acute myeloid leukemia undergoing allogeneic stem‐cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry2023 · 8 citations
  4. 4Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT2023 · 15 citations
  5. 5Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study2015 · 456 citations